Jpn J Clin Oncol 2010, 40:388–394 PubMedCrossRef 21 Wollscheid V

Jpn J Clin Oncol 2010, 40:388–394.PubMedCrossRef 21. Wollscheid V, Kuhne-Heid R, Stein I, et al.: Identification of a new proliferation-associated protein NET-1/C4.8 characteristic for a subset of high-grade cervical intraepithelial neoplasia and cervical carcinomas. International

journal of cancer. J Int Canc 2002, 99:771–775.CrossRef 22. Ecimovic P, Murray D, Doran P, et al.: Direct effect of morphine on breast cancer cell function in vitro: role of the NET1 gene. Br J Anaesth 2011,107(6):916–923.PubMedCrossRef 23. Rockett JC, Larkin K, Darnton SJ, et al.: Five newly established oesophageal carcinoma cell lines: phenotypic and immunological characterization. Br J Canc 1997, 75:258–263.CrossRef 24. Abdel-Latif MM, O’Riordan Tipifarnib solubility dmso J, Windle HJ, et al.: NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett’s metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg

2004, 239:491–500.PubMedCrossRef 25. Kang Y, Massague J: Epithelial-buy PLX4032 mesenchymal transitions: twist in development and metastasis. Cell 2004, 118:277–279.PubMedCrossRef 26. Thiery JP, Morgan M: Breast cancer progression with a Twist. Nat Med 2004, 10:777–778.PubMedCrossRef 27. Yang J, Mani SA, Donaher JL, et al.: Twist, a master regulator of morphogenesis, Dibutyryl-cAMP cell line plays an essential role in tumor metastasis. Cell 2004, 117:927–939.PubMedCrossRef 28. Andl CD, McCowan KM, Allison GL, et al.: Cathepsin B is the driving force of esophageal cell invasion in a fibroblast-dependent manner. Neoplasia 2010, 12:485–498.PubMed 29. Bhowmick

NA, Ghiassi M, Bakin A, et al.: Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 2001, 12:27–36.PubMedCrossRef 30. Nakaya Y, Sukowati EW, Wu Y, et al.: RhoA and microtubule dynamics control cell- basement membrane interaction in EMT during gastrulation. Nat Cell Biol 2008, 10:765–775.PubMedCrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions CL: study concept and design, experimental work and acquisition of data, drafting of the manuscript, analysis and interpretation of data, critical revision of the manuscript for important intellectual content. EC, RC, GP: 4-Aminobutyrate aminotransferase experimental work and acquisition of data, interpretation of data, critical revision of the manuscript for important intellectual content of the manuscript. PD, JR: analysis and interpretation of data, drafting of the manuscript critical revision of the manuscript for important intellectual content of the manuscript. PMM: study concept and design, analysis and interpretation of data, critical revision of the manuscript for important intellectual content of the manuscript. DM: study concept and design, experimental work and acquisition of data, critical revision of the manuscript for important intellectual content of the manuscript. All authors read and approved the final manuscript.

Comments are closed.